Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond spirometry in COPD: expanding the diagnostic paradigm.

ERJ open research·2026

Same author

Performance of multivariable risk prediction algorithms in predicting COPD exacerbations: a population-based study.

Thorax·2026

Same author

Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials.

American journal of respiratory and critical care medicine·2026

Same author

Exploring COPD Participants' Experiences in a Comprehensive Telewellness Program within a Mixed-Disability Cohort: A Qualitative Study.

International journal of chronic obstructive pulmonary disease·2026

Same author

Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial.

American journal of respiratory and critical care medicine·2026

Same author

Rural <i>versus</i> urban living and COPD: a systematic review.

European respiratory review : an official journal of the European Respiratory Society·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Defining disease stability in COPD: Evidence from Phase 3 clinical trials.

Dave Singh^1,2, Rianne Stacey³, David M G Halpin⁴

¹Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.

American Journal of Respiratory and Critical Care Medicine

|June 12, 2026

Summary

Achieving disease stability in chronic obstructive pulmonary disease (COPD) is an attainable treatment goal. Stable COPD patients experienced significantly fewer exacerbations and lower mortality risk, highlighting stability as a key therapeutic target.

Keywords:

Chronic Obstructive Pulmonary Disease Disease Stability Patient-Reported Outcome Measure Prompt Optimization Treatment Outcome

More Related Videos

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

Related Experiment Videos

Last Updated: Jun 13, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

Area of Science:

Pulmonology
Respiratory Medicine
Clinical Trials

Background:

Chronic obstructive pulmonary disease (COPD) stability represents a low disease activity state.
Disease stability is increasingly recognized as a critical treatment target in COPD management.

Purpose of the Study:

To characterize COPD stability as a composite endpoint.
To evaluate the prognostic value of achieving COPD stability on subsequent clinical outcomes.

Main Methods:

Post hoc analyses of clinical trials (IMPACT, FULFIL, MATINEE/METREX/METREO) involving fluticasone furoate/umeclidinium/vilanterol and mepolizumab.
Stability defined as absence of moderate/severe exacerbations and no worsening in CAT and FEV1 from baseline.
Bayesian joint modeling assessed the probability of achieving stability and its association with exacerbations and all-cause mortality (ACM).

Main Results:

Stability was achieved by 22% (IMPACT) and 46% (FULFIL) of patients with triple therapy, and 18% with mepolizumab. Triple therapy and mepolizumab showed higher stability rates compared to dual therapy and placebo.
Patients achieving stability at Week 28 had a 45.7% reduced risk of exacerbations and a 51.7% reduced risk of ACM post-Week 28.
Clinically meaningful improvements in CAT and FEV1 were observed in patients achieving stability.

Conclusions:

Disease stability in COPD is an achievable treatment target.
Achieving stability predicts significant long-term benefits, including reduced exacerbations and mortality.
These findings support disease stability as a valuable endpoint in COPD clinical trials and practice.